Key Takeaways
- • Jeffrey Tarrant, founder and chairman of Protégé Partners and MOV37, died August 5, 2019, at age 63 from brain cancer, which was first diagnosed and treated in 2017.
- • Tarrant was a pioneering hedge fund investor with over three decades of experience identifying and backing emerging talent, including future stars Bill Ackman and Marc Lasry before their prominence.
- • He gained significant visibility in the industry through Protégé Partners' high-profile wager against Warren Buffett, betting that hedge funds would outperform the stock market over an extended period.
- • A Harvard Business School graduate, Tarrant held leadership positions across multiple investment platforms and served as a board member for WITNESS, demonstrating influence beyond traditional hedge fund management.
Summary
Tarrant founded Protégé Partners, a New York-based investment manager, and later established MOV37, serving as chairman of both firms. His career spanned more than three decades in talent identification and capital deployment within the hedge fund ecosystem. He gained recognition for his ability to identify promising hedge fund managers before they achieved widespread recognition, notably backing Bill Ackman and Marc Lasry during their early stages.
The investor gained additional prominence through Protégé Partners' well-publicized wager with Warren Buffett, in which his firm bet that actively managed hedge funds would outperform the broader stock market over an extended timeframe—a position that highlighted the ongoing debate over active versus passive investment strategies during the 2010s.
Tarrant held a Harvard Business School degree and maintained involvement in philanthropic and governance roles beyond asset management, serving on the board of WITNESS, an international human rights organization. His death removes a significant voice from the hedge fund community at a time when questions about active management performance and fee structures continue to dominate industry discourse.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.